gila sources

A narrative review on tirzepatide's therapeutic potential in glycemic control and cardioprotection.

2026 · Diabetes · — · PMID 41496949 · 1 outcomes

Tirzepatide, a dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, represents a new class of incretin-based therapy for type 2 diabetes mellitus (T2DM), obesity,

Diabetes Remission in Drug-Naïve Patients with Type 2 Diabetes After Efsubaglutide Alfa Treatment.

2026 · Diabetes · — · PMID 41498879 · 2 outcomes

Efsubaglutide alfa is a novel, long-acting GLP-1RA, which imparts human homology, molecular flexibility and enhanced GLP-1 receptor-specific binding. This drug-free, observational follow-up evaluated remission and durabi

A FIDELITY Analysis on Finerenone With SGLT-2i and GLP-1RA in CKD.

2026 · Diabetes · — · n=167 · PMID 41630895

Finerenone demonstrated kidney and cardiovascular benefits in participants with chronic kidney disease (CKD) and type 2 diabetes (T2D) on optimized renin-angiotensin system (RAS) inhibition in FIDELITY, a pooled individu

The future of PCOS management: Disease modification through regenerative, metabolic, and digital therapeutics.

2026 · PCOS · — · PMID 41666555

Polycystic ovary syndrome (PCOS) represents the leading endocrine problem affecting women of reproductive age, leading to serious complications related to reproduction, metabolism, and psychosocial aspects. Nonetheless,

Characterisation of real-world patients who discontinued a glucagon-like peptide-1 agonist.

2026 · Diabetes · — · PMID 41713959 · 2 outcomes

The objective of this analysis was to identify the 6-month discontinuation rate for GLP-1 analogues, reasons for discontinuation, and characteristics associated with discontinuation. This was a retrospective analysis of

Is semaglutide a better weight-management option than bariatric surgery for patients undergoing total knee arthroplasty?

2026 · GLP-1 general · — · PMID 41718773

BACKGROUND: Bariatric surgery has been associated with increased risks of revision surgery following total knee arthroplasty (TKA), raising concerns about its safety for weight management in this population. Semaglutide,

Weight regain after bariatric surgery: A framework for management.

2026 · GLP-1 general · — · PMID 41733456

Obesity is a complex, multifactorial disease. Rates of obesity are rising worldwide. Bariatric surgery is the most effective treatment for obesity, as it results in the greatest weight loss as well as significant improve

Trends in 1-year persistence and adherence among initiators of high-potency, weight loss-indicated glucagon-like peptide 1 receptor agonists.

2026 · Diabetes · — · PMID 41760566

Despite the clinical efficacy of glucagon-like peptide-1 receptor agonists (GLP-1RAs) for weight loss, real-world persistence remains substantially lower than seen in clinical trials. Since 2021, GLP-1RA shortages and ch

Efficacy and Safety of Once-Weekly IcoSema Versus Once-Daily IDegLira in People with Type 2 Diabetes: Systematic Literature Review and Network Meta-analysis.

2026 · Diabetes · — · PMID 41762380

For people with type 2 diabetes (T2D), combination therapy with a basal insulin and a glucagon-like peptide 1 receptor agonist (GLP-1 RA) can improve glycaemic control, lower hypoglycaemia risk, and improv

Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial.

2026 · Diabetes · — · n=424 · PMID 41765029

Orforglipron is a novel non-peptide (GLP-1) receptor agonist designed for daily oral administration without food or water restrictions. This study aimed to compare the efficacy and safety of orforglipron with oral semagl

Post-sleeve gastrectomy weight loss: Role of botulinum toxin and semaglutide injections.

2026 · GLP-1 general · — · PMID 41777326

Comparison of the therapeutic effects of endoscopic botulinum toxin (BTX) injection and semaglutide (SME) injection in treatment of patients with obesity and weight regain after laparoscopic sleeve gastrectomy (LSG). The

Real-World Evidence of Tirzepatide in Indian Adults With Type 2 Diabetes: Significant Early Glycemic and Cardiometabolic Benefits.

2026 · Indian-specific · India · n=71 · PMID 41798487 · 1 outcomes

Multicenter Indian RWE (n=71): HbA1c −1.8%, weight −5.7% at 12 weeks; discontinuation 22.2% mainly GI intolerance and cost.

Prevalence and Predictors of Hair Shedding among GLP-1 Receptor Agonist Users: A Cross-Sectional Study from Saudi Arabia.

2026 · GLP-1 general · — · n=107 · PMID 41799300 · 5 outcomes

Although glucagon-like peptide-1 receptor agonists (GLP-1 RAs) demonstrate remarkable efficacy for weight management, emerging pharmacovigilance data suggest an increased hair loss risk, particularly with newer agents. T

Obesity Treatments and Weight Changes in Clinical Practice After Discontinuation of Semaglutide or Tirzepatide.

2026 · GLP-1 general · — · PMID 41816857 · 2 outcomes

To describe obesity treatments in real-world settings after discontinuation of semaglutide or tirzepatide and variability in weight change post-discontinuation. This retrospective cohort study used electronic health reco

A qualitative study exploring experiences about using semaglutide for weight loss in a rural setting in Denmark - 'she is probably on the meds'.

2026 · GLP-1 general · — · PMID 41838446

Semaglutide has gained attention for its efficacy in weight loss. However, little is known about patients' experiences. This study explores patient experiences with using Semaglutide for weight loss (SEMA-WL) in a rural

Clinical Management of Weight Regain and Cardiometabolic Consequences After Discontinuation of GLP-1 Receptor Agonists.

2026 · GLP-1 general · — · PMID 41889156 · 1 outcomes

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dual incretin therapies produce substantial weight loss and cardiometabolic improvement, yet treatment discontinuation is common and associated with adverse metabo

Resistant and Refractory Obesity: The Complexity of Anti-Obesity Therapy Failure.

2026 · GLP-1 general · — · PMID 41898403

Pharmacotherapy is a key component of obesity management, yet treatment failure remains a prevalent challenge in clinical practice. Such failure may present as insufficient pharmacological response, early discontinuation

New Drugs on the Block: Dietary Management and Nutritional Considerations During the Use of Anti-Obesity Medication.

2026 · GLP-1 general · — · PMID 41901137

Incretin-based pharmacotherapy has rapidly transformed obesity management. However, despite its efficacy, gastrointestinal (GI) adverse events (AEs) are common and represent a major driver of treatment discontinuation. S

Weight Regain After GLP-1-Based Therapy Discontinuation: Failure, Physiology, or Follow-Up Gap.

2026 · GLP-1 general · — · PMID 41909366

The introduction of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual incretin agonists targeting both the GIP and GLP-1 receptors (GIP/GLP-1 dual agonists) has reshaped obesity management, approaching degre

Childhood obesity and cardiac risk in youth: Emerging challenges toward 2050.

2026 · GLP-1 general · — · PMID 41933725

Pediatric obesity is increasing at an alarming rate, affecting over 381 million children worldwide and emerging as a critical public health issue. According to World Health Organization (WHO) 2016, 40% of adults are over

Weight Loss With GLP-1 Agonists in Nondiabetic Adults: Systematic Review and Network Meta-Analysis.

2026 · Diabetes · — · PMID 41936548

Two glucagon-like peptide-1 receptor agonists (GLP-1 RAs) (semaglutide and liraglutide) and one dual agonist (tirzepatide) are FDA-approved for weight loss in adults with obesity without type 2 diabetes mellitus. This sy

Trajectory of weight regain after cessation of GLP-1 receptor agonists: a systematic review and nonlinear meta-regression.

2026 · GLP-1 general · — · PMID 41938838 · 5 outcomes

SR/MA: 60% of lost weight regained at 1 year; half-life 23 weeks; extrapolated plateau 75.3% beyond 52 weeks.

Real-World Clinical Evidence of Tirzepatide for Metabolic Abnormalities in Subjects With Type 2 Diabetes: The Multicenter Retrospective Observational Hokkaido-TZP Study.

2026 · Diabetes · — · PMID 41944182

Tirzepatide has demonstrated potent glucose-lowering efficacy and metabolic benefits in subjects with type 2 diabetes (T2D) in Phase III clinical trials. However, its efficacy in real-world clinical practice, particularl

Real-world weight impact upon tirzepatide discontinuation at a single-center endocrinology clinic in patients with overweight or obesity.

2026 · Diabetes · — · n=68 · PMID 41962807 · 2 outcomes

Overweight and obesity are major contributors to cardiovascular-kidney-metabolic (CKM) disease. Tirzepatide (TZP-MJ), originally approved for type 2 diabetes (T2D), has shown significant weight loss beyond glycemic impro

Preferred Glucagon-like Peptide-1 Receptor Agonists in Adults With Type 2 Diabetes and Established Cardiovascular Disease or High Cardiovascular Risk: A Network Meta-analysis of Randomized Trials.

2026 · Diabetes · — · n=83 · PMID 41967797

The comparative cardiovascular (CV) efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in patients with type 2 diabetes (T2D) and established cardiovascular disease (CVD) or high CV risk remain

Weight "regain" in obesity shifts responsibility from biology to personal inadequacy.

2026 · GLP-1 general · — · PMID 41974489

Weight "regain" in obesity shifts responsibility from biology to personal inadequacy.

Reversion to normoglycemia with tirzepatide vs semaglutide in participants with obesity and prediabetes: a post hoc analysis of SURMOUNT-5.

2026 · Diabetes · — · PMID 42002673

BACKGROUND: Prevention of progression into type 2 diabetes (T2D) in patients with prediabetes is a key goal of obesity management. In SURMOUNT-5, once weekly tirzepatide at the maximum tolerated dose (MTD 10 mg or 1

Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial.

2026 · Diabetes · — · PMID 42012820

This study evaluated the cost-effectiveness (from the United States [US] societal perspective) of tirzepatide at its maximum-tolerated-dose (MTD) compared to semaglutide (MTD), both administered adjunct to a reduced-calo

Clinical outcomes of glucagon-like peptide-1 receptor agonist therapy in kidney transplant recipients: a systematic review and meta-analysis.

2026 · Diabetes · — · PMID 42017027 · 1 outcomes

Metabolic complications after kidney transplantation (KT) significantly affect graft and patient survival. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) offer cardio-renal benefits in the general population, but e

Enhancing economic modelling in obesity: integrating novel type 2 diabetes progression & obstructive sleep apnea remission - a UK case study.

2026 · Diabetes · — · PMID 42021523

This study presents an updated health economic model for evaluating the long-term cost-effectiveness of interventions in overweight and obesity, integrating new clinical evidence from the SURMOUNT clinical trial programm

Sequential Intragastric Balloon Followed By GLP-1 Receptor Agonist Therapy in Obesity: A Comparative Study of 12-Month Weight Loss Outcomes.

2026 · GLP-1 general · — · PMID 42026424

BACKGROUND: Endoscopic and pharmacological therapies are well-established non-surgical options for obesity management. Although combined use of intragastric balloon (IGB) and glucagon-like peptide-1 receptor agonists (GL

Real-World Comparison of Short-Term Adverse Events, Treatment Persistence, and Efficacy of Semaglutide and Tirzepatide: A Nationwide Multicenter Study.

2026 · Diabetes · — · PMID 42030208

Real-world data directly comparing the safety, tolerability, and effectiveness of semaglutide and tirzepatide in patients with obesity remain limited. This nationwide multicenter observational study compared short-term a

Six-Month Real-World Effectiveness, Persistence and Safety of Low-to-Moderate Dose Tirzepatide in Adults With Obesity: A Multicentre Observational Study.

2026 · GLP-1 general · — · PMID 42037110 · 3 outcomes

To evaluate 6-month weight-loss outcomes, treatment persistence, and safety of low- to moderate-dose tirzepatide in a real-world clinical setting. This multicentre retrospective observational study evaluated adults with

[Tirzepatide in real-world clinical practice: changes in body composition and muscle function in patients with obesity].

2026 · GLP-1 general · — · PMID 42037504 · 1 outcomes

obesity is a chronic and relapsing disease. Tirzepatide, a dual GLP-1 and GIP receptor agonist, has demonstrated weight loss exceeding 20 % at higher doses. However, real-world data remain limited, particularly regarding

Indirect Comparative Efficacy and Safety of Tirzepatide Versus Oral Semaglutide for the Treatment of Overweight and Obesity.

2026 · Diabetes · — · PMID 42050884

Tirzepatide, an injectable glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist (RA), is approved for weight management in several regions. Oral GLP-1 RAs, such as semag

Semaglutide in obesity and type 2 diabetes: A review of clinical trial evidence from 1 to 5 semaglutide treatment effect in people with obesity program.

2026 · Diabetes · — · PMID 42060800 · 1 outcomes

Obesity and type 2 diabetes mellitus (T2DM) are widespread health concerns that often coexist, contributing to increased cardiometabolic risks and premature death. Despite advancements in both lifestyle interventions and

Data-driven prioritization of high-risk individuals for weight loss interventions.

2026 · GLP-1 general · — · PMID 42062622

New obesity medications have demonstrated efficacy in trials, but their real-world deployment is partly limited by the absence of approaches that identify individuals for treatment based on risks for obesity-related comp

Tirzepatide-associated interstitial kidney injury.

2026 · Diabetes · — · PMID 42093865

We report a case of interstitial nephritis, likely secondary to tirzepatide. A 66-year-old man with type 2 diabetes, stage 3b chronic kidney disease, and other metabolic comorbidities experienced a progressive decline in

Pharmacological therapy in the obese patient: is it only a matter of fat loss?

2026 · GLP-1 general · — · PMID 42099474

Obesity is a chronic, multifactorial condition strongly associated with increased cardiovascular and metabolic risk, as well as the development of systemic complications. Recent evidence from randomized controlled trials

Effect of Tirzepatide on Health-Related Quality of Life in Japanese Patients With Obesity Disease: Patient-Reported Outcomes From the SURMOUNT-J Study.

2026 · Diabetes · — · PMID 42108080

We evaluated the impact of tirzepatide on health-related quality of life (HR-QoL) in Japanese individuals with obesity disease from the phase 3 SURMOUNT-J trial. Japanese adults with obesity disease without diabetes were

Kidney outcomes with GLP-1 receptor agonists in people with type 2 diabetes already receiving SGLT2 inhibitors: a target trial emulation study using UK primary care data.

2026 · Diabetes · — · PMID 42109572

Type 2 diabetes is the leading cause of kidney failure and is predominantly managed in primary care. Large randomised trials have shown that GLP-1 receptor agonists and SGLT2 inhibitors each slow kidney disease progressi

Effectiveness of GLP-1 Receptor Agonists in Patients With Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.

2026 · PCOS · — · PMID 42116999 · 1 outcomes

18 RCTs: GLP-1 RAs reduced BMI vs control (MD −1.09 kg/m²). PCOS metabolic endpoints — not STEP-1 obesity-trial WL%.

Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial.

2026 · GLP-1 general · — · PMID 42119587 · 1 outcomes

Obesity treatment improves long-term health and quality of life outcomes. Weight reduction and its maintenance play an important role in achieving these goals. We evaluated the efficacy and safety of continuing tirzepati

Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial.

2026 · GLP-1 general · — · PMID 42120723 · 1 outcomes

Incretins have improved the management of obesity and its related complications, but maintaining these health benefits requires ongoing administration, which can be challenging. Orforglipron, a once-daily oral nonpeptide

GLP-1 Receptor Agonist Combination Therapy Before and After Metabolic and Bariatric Surgery: A Review of Outcomes.

2026 · GLP-1 general · — · PMID 42124784

The paradigm of obesity treatment is rapidly evolving with the introduction and widespread adoption of glucagon-like peptide-1 receptor agonists (GLP-1 RAs). Semaglutide, the representative agent, has demonstrated substa

Decoding the hallmarks of GLP-1RA weight-loss super-responders.

2026 · GLP-1 general · — · PMID 42147968 · 1 outcomes

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have reshaped obesity treatment, yet weight-loss outcomes remain highly uneven in real-world care. Using a federated biomedical platform, we analyzed 135 349 indi

GLP-1 receptor agonists and surgical care: implications for bariatric Procedures, perioperative Outcomes, and nutritional optimization.

2026 · Diabetes · — · PMID 42155603

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly used for obesity and type 2 diabetes and are now frequently encountered in patients undergoing bariatric and other elective surgeries. Their effects o

DUAL GIP/GLP-1Ra reduces residual proteinuria in non-diabetic fabry disease.

2026 · Diabetes · — · PMID 42159298

Residual proteinuria remains a major determinant of renal disease progression in Fabry disease (FD) despite optimized enzyme replacement or chaperone therapy and maximal renin-angiotensin system (RAS) blockade. Dual gluc

Comment on Sattar et al. Weight Reduction With Tirzepatide Varied Meaningfully by Baseline HbA1c Category in Adults With Overweight or Obesity and Type 2 Diabetes in SURMOUNT-2. Diabetes Care 2025;48:e136-e137.

2026 · Diabetes · — · PMID 42160590

Comment on Sattar et al. Weight Reduction With Tirzepatide Varied Meaningfully by Baseline HbA1c Category in Adults With Overweight or Obesity and Type 2 Diabet

Weight trajectories after last tirzepatide or semaglutide prescription across a federated health network.

2026 · GLP-1 general · — · PMID 42163990 · 1 outcomes

GLP-1 receptor agonist (GLP-1RA) discontinuation has been associated with weight regain. However, weight trajectories following the last documented GLP-1RA prescription in the real-world clinical setting have not been ex

ICER report demonstrates both the value and challenges in financing of weight loss medications.

2026 · Diabetes · — · PMID 42166309

Two out of 5 US adults live with obesity, generating substantial clinical and economic burden. Recent glucagon-like peptide-1 receptor agonists (GLP-1 RAs), including semaglutide and tirzepatide, demonstrate significant

Causes and consequences of discontinuation of GLP1RAs or tirzepatide.

2026 · Diabetes · — · PMID 42168641

Glucagon-like peptide 1 (GLP1) receptor (GLP1R) agonists and tirzepatide, a dual GLP1R and glucose-dependent insulinotropic polypeptide receptor agonist, have become fundamental in managing type 2 diabetes mellitus (T2DM

Projected reduction in major adverse cardiovascular events among high-risk U.S. adults with type 2 diabetes eligible for oral semaglutide: a SOUL trial-based analysis using NHANES (1988-2018) cycles.

2026 · Diabetes · — · PMID 42169198 · 1 outcomes

BACKGROUND: Oral semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), has been shown to reduce major adverse cardiovascular events (MACE) in high-risk individuals with type 2 diabetes in the SOUL trial. It

To Reenvision and Redefine: Considering the Role of Lifestyle Interventions in the New Era of Second-Generation Obesity Management Medications.

2026 · GLP-1 general · — · PMID 42183911

This narrative review examines lifestyle considerations before, during, and after second-generation obesity management medication (OMM) treatment. Second-generation OMMs, including semaglutide and tirzepatide, have demon

Tirzepatide data: safety first is safety always!

2026 · Diabetes · — · PMID 42201797

Tirzepatide, a dual GIP and GLP-1 receptor agonist, offers unprecedented efficacy for type 2 diabetes and obesity. Due to its rapid global adoption, understanding its complete safety spectrum is urgently needed to guide

Lifestyle First and Lifestyle Always, Does Not Mean Lifestyle Only: Reimagining Cardiometabolic Care in the Era of GLP-1 Receptor Agonists.

2026 · Diabetes · — · PMID 42206250

The rapid uptake of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), including semaglutide and tirzepatide, has transformed the management of obesity, diabetes, and cardiometabolic disease, producing substantial we

Insulin Sensitivity and Beta Cell Function With Macupatide Alone or With Dulaglutide in Type 2 Diabetes: A Phase 1b, Randomised Controlled Trial.

2026 · Diabetes · — · PMID 42229460

This Phase 1b, randomised, double-blind clinical trial investigated the contribution of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) to insulin sensitivity and secretion in peopl

Rates of, Reasons for, and Reactions to Discontinuation of GLP-1 Receptor Agonists: A Narrative Review.

2026 · Diabetes · — · PMID 42244474

GLP-1RAs are increasingly used for their glucose-lowering and weight-management effects, but many patients discontinue them. In this narrative review we aim to review real-world, quantitative and qualitative GLP-1RA disc

Tirzepatide for Recurrent Weight Gain after Bariatric Procedures: Real-World Evidence of Efficacy and Safety.

2026 · GLP-1 general · — · PMID 42247124

Recurrent weight gain after bariatric surgery (BS) or endoscopic bariatric therapy (EBT) remains a long-term clinical challenge, potentially undermining long-term treatment success. Tirzepatide, a dual agonist of the glu

Patient Experiences With GLP-1 Receptor Agonists.

2026 · Diabetes · — · PMID 42247231

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are transformational therapies in the treatment of obesity; yet discontinuation rates are high, and patients experience rapid weight regain after stopping treatment.

Dose-Response and Clinical Equivalence of Semaglutide and Tirzepatide for Weight Loss in Type 2 Diabetes: A Model-Based Analysis.

2026 · Diabetes · — · PMID 42252377

Semaglutide and tirzepatide are highly effective incretin-based therapies for weight reduction in individuals with type 2 diabetes (T2DM). However, direct comparisons across the full range of clinically relevant dos

Retrospective Comparative Study of Oral Versus Subcutaneous Semaglutide in Patients with Type 2 Diabetes Mellitus.

2026 · Diabetes · — · n=232 · PMID 42278227

Semaglutide represents a unique therapeutic option for patients with type 2 diabetes mellitus (T2DM), being the first and currently only glucagon-like peptide-1 receptor agonist (GLP-1RA) available in both subcutaneous a

Nutrition-First Support for GLP-1 and Dual Incretin Therapy in Obesity: A Practical Framework for Dietary Management, Symptom Tolerability, and Long-Term Weight Maintenance.

2026 · GLP-1 general · — · PMID 42280393

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists have transformed obesity treatment, producing substantial weight loss during active

Impact of Preoperative Semaglutide Discontinuation Timing on Postoperative Outcomes in Aesthetic Abdominoplasty: A Retrospective Comparative Study.

2026 · Diabetes · — · PMID 42286330

The widespread adoption of GLP-1 receptor agonists such as semaglutide for weight loss has led to an increasing number of non-diabetic patients seeking body contouring procedures after pharmacologic weight reduction. How

Post hoc analysis of SURMOUNT-J: tirzepatide versus placebo and predicted 10-year cardiovascular disease risk in Japanese adults with obesity disease.

2026 · Diabetes · — · PMID 42287159

Obesity management is central to reducing cardiovascular disease (CVD) risk. In the phase 3 SURMOUNT-J trial, tirzepatide significantly reduced body weight and improved cardiometabolic parameters versus placebo in Japane

Effectiveness of tirzepatide in Japanese patients with type 2 diabetes but no obesity: A sub-analysis of Hokkaido-TZP study data.

2026 · Diabetes · — · PMID 42289805

Although tirzepatide efficaciously reduces glucose concentrations and weight, phase 3 trials evaluated patients with a body mass index (BMI) ≥23 kg/m2. Consequently, clinical evidence in patients with type

Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Treatment After Liver Transplantation: A Hypothesis-Generating Case Report.

2026 · Diabetes · — · PMID 42291858

Glucagon-like peptide-1 receptor agonists (GLP1RAs) are widely used for the management of type 2 diabetes (T2D) and obesity, yet their safety profile in liver transplant recipients remains insufficiently characterized. W

Tirzepatide for Obesity in Adults ≥ 65 Years: A Post Hoc Analysis of the SURMOUNT and SUMMIT Clinical Trials.

2026 · GLP-1 general · — · PMID 42303274

Tirzepatide is a once-weekly glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA) approved for weight management in adults with obesity. Data on older adults remain

GLP1 receptor agonists in heart failure with preserved ejection fraction (HFpEF) - beyond weight loss: a condensed scientific review.

2026 · Diabetes · — · PMID 42306018

More than half of cases of heart failure (HF) now occur with preserved ejection fraction (HFpEF), a heterogeneous syndrome strongly influenced by comorbidities such as obesity, hypertension, diabetes and atrial fibrillat

Weight-Lowering Drugs and Natural Female Fertility-A Systematic Review and Meta-Analysis.

2026 · GLP-1 general · — · PMID 42307450

Overweight and obesity are global health concerns linked to impaired female fertility. Weight-lowering drugs are an alternative for achieving weight loss; however, their effect on natural female fertility is unclear. A s

A Computational Trial of Dermal Mechanotransduction in GLP-1 Receptor Agonist-Associated Premature Facial Ageing.

2026 · GLP-1 general · — · PMID 42310090

The efficacy of non-invasive ultrasound skin tightening (e.g., Sofwave) relies on fibroblast mechanotransduction, a process impaired in obesity. The widespread use of GLP-1 receptor agonists (GLP-1RAs) like semaglutide f

Tirzepatide and the Cardiovascular Continuum: Metabolic, Cardiorenal and Heart Failure Evidence.

2026 · Diabetes · — · PMID 42317617

Tirzepatide is a first-in-class, once-weekly dual GIP and GLP-1 receptor agonist approved for type 2 diabetes and obesity. Given the tight link between hyperglycemia, adiposity, and cardiovascular disease, tirzepatide ha

Long-term effects of weight-reducing drugs in people with hypertension.

2026 · GLP-1 general · — · PMID 42318855

Long-term weight management drugs have the potential to reduce body weight and blood pressure in obese or overweight individuals. Being overweight or obese is often associated with hypertension, which is linked to an inc

Effect of GLP-1 receptor agonists at doses for obesity management on muscle health: systematic review and meta-analysis of randomized controlled trials (RCTs).

2026 · GLP-1 general · — · PMID 42321502 · 1 outcomes

7 RCTs (n=821): absolute lean mass −1.74 kg; lean mass as % of total weight +1.81%. Nutrition + resistance training recommended.

Adjunctive Dulaglutide in Relapsing-Remitting Multiple Sclerosis: A Randomized Open-Label Proof-of-Concept Trial.

2026 · GLP-1 general · — · PMID 42321509

Multiple sclerosis (MS) is an immune-mediated inflammatory and neurodegenerative disease of the central nervous system (CNS) that leads to demyelination, axonal injury, and progressive disability. Glucagon-like peptide&#

Short- and long-term effects of semaglutide 2.4 mg on energy intake, appetite, and food reward: a 60-week, double-blind randomized controlled trial.

2026 · GLP-1 general · — · PMID 42323166

Studies of ≤20 wk have demonstrated reductions in energy intake, appetite, and food reward with semaglutide that may drive initial weight loss. These brief studies could not assess whether semaglutide has long-ter

Perinatal Semaglutide Treatment Improves Maternal Health and Mitigates Offspring Metabolic Dysfunction in a Mouse Model of Maternal Obesity.

2026 · Diabetes · — · PMID 42327337

Early-life exposures during critical periods of development significantly impact lifelong metabolic risk and likely contribute to the rising rates of obesity, type 2 diabetes, and metabolic dysfunction-associated steatot

Obesity Management Pharmacotherapies and Lifestyle Treatment for Pediatric Obesity Management: A Systematic Review and Network Meta-Analysis.

2026 · GLP-1 general · — · PMID 42329656

Pediatric obesity is a global health challenge. Although health behavior and lifestyle treatment (HBLT) is foundational, the comparative effectiveness of HBLT, various pharmacotherapies, and their combinations remains un

Dual Glucagon and GLP-1 Receptor Agonist Survodutide Improves Biomarkers of Beta-Cell Function and Insulin Sensitivity in People With Type 2 Diabetes or Living With Overweight/Obesity.

2026 · Diabetes · — · PMID 42331726

This post hoc analysis evaluated the effect of survodutide on beta-cell function, insulin sensitivity, and glucose biomarkers in two phase 2 trial populations. Trial 1404-0002 randomised 413 participants with type 2 diab

Experience with Tirzepatide and Weight Management During and After a Clinical Trial in Japanese Patients with Obesity Disease: A Qualitative Study.

2026 · GLP-1 general · — · PMID 42334799 · 1 outcomes

The phase 3 SURMOUNT-J clinical trial showed that Japanese adults with obesity disease achieved clinically meaningful body weight loss with once-weekly tirzepatide for 72 weeks. The primary objective of the pre